MarketPeel
Insider Trading Intelligence
GN

George K. Ng

PCSA
CHIEF EXECUTIVE OFFICER · PROCESSA PHARMACEUTICALS, INC. · CIK 0001638744
FILING MIX · LIFETIME100%/0%
BUYS
23
SELLS
0
TOTAL VALUE
$201.6K
COMPANIES
2
ACTIVE SINCE
Aug 2023
HOLDINGS NOW
171,732
AVG SELL PX
TRADE KIND
SHOWING 23 / 23
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 15 pending
Forward-return performance of every backtestable P/S trade by George K. Ng, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+83.33%+6.17%+1.08%+5.08%+8.14%
14d6+66.67%+3.18%+3.35%-0.17%+4.65%
30d6+50.00%-1.40%+5.95%-6.60%-3.69%
60d6+33.33%-17.02%+1.82%-28.05%-30.18%
90d6(2 pending)+0.00%-34.12%+5.15%-39.27%-38.43%
180d6(4 pending)+0.00%-48.65%+9.15%-57.80%-57.80%
1y6(4 pending)+0.00%-78.60%+20.28%-98.88%-98.88%
2y6(5 pending)+0.00%-95.35%+43.63%-138.98%-138.98%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PCSA · 15,492 shares · as of Jul 1, 2026
0480,618961,2361,441,8531,922,471202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 23 buys / 0 sellsCOVERAGE · 13 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
3,057$1.93$5.9K15,492Jul 1, 2026Jul 1, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
2,465$2.22$5.5K12,435Jun 15, 2026Jun 16, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
2,129$2.57$5.5K9,970May 29, 2026Jun 1, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
1,843$2.97$5.5K7,841May 15, 2026May 19, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
2,034$2.69$5.5K6,013Apr 30, 2026May 1, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
1,843$2.97$5.5K5,492Apr 15, 2026Apr 17, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
1,843$2.97$5.5K3,979Apr 15, 2026Apr 30, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
1,843$2.97$5.5K3,979Apr 15, 2026May 19, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
2,136$2.54$5.4K3,649Mar 31, 2026Apr 1, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
2,136$2.54$5.4K2,136Mar 31, 2026Apr 30, 2026View →
HURA
TUHURA BIOSCIENCES, INC./NV
PURCHASEGRANT
Stock grant
156,240156,240Feb 12, 2026Feb 17, 2026View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
256,000256,000Oct 1, 2025Oct 3, 2025View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
768,000768,000Oct 1, 2025Oct 3, 2025View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,822,4711,922,471Jul 24, 2025Jul 28, 2025View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
43,60043,600Jan 29, 2025Feb 18, 2025View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
87,20087,200Jan 29, 2025Feb 18, 2025View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
87,200$0.80$69.5K87,200Jan 27, 2025Jan 29, 2025View →
HURA
TUHURA BIOSCIENCES, INC./NV
PURCHASEGRANT
Stock grant
51,27551,275Jan 2, 2025Jan 6, 2025View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASE
Chief Executive Officer
10,000$2.70$27.0K20,000Jan 30, 2024Jan 31, 2024View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
100,000$0.25$25.0K200,000Oct 12, 2023Oct 12, 2023View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
100,000$0.25$25.0K100,000Oct 10, 2023Oct 10, 2023View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
400,000800,000Aug 8, 2023Aug 9, 2023View →
PCSA
PROCESSA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
400,000400,000Aug 8, 2023Aug 9, 2023View →
Other insiders · PCSA
Loading peer insiders…
About this filer
CIK 0001638744
ROLE
Chief Executive Officer
PRIMARY
PCSA
COMPANIES
2
ACTIVE SINCE
Aug 2023
MARKETPEEL · /INSIDER/0001638744DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback